| 臺大學術典藏 |
2022-01-24T09:31:24Z |
Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study
|
Yu M.-W.; Lin C.-L.; CHUN-JEN LIU; Yang S.-H.; Tseng Y.-L.; Wu C.-F. |
| 國立成功大學 |
2022 |
Pulmonary function changes after uniportal video-assisted thoracoscopic anatomical lung resection
|
Dai, S.-Y.;Tseng, Y.-L.;Chang, Chang C.-C.;Huang, W.-L.;Yen, Yen Y.-T.;Lai, W.-W.;Chen, Y.-Y. |
| 國立成功大學 |
2022 |
The surgical resection of the primary tumor increases survival in patients with EGFR-mutant advanced non-small cell lung cancer: a tertiary center cohort study
|
Chen, Y.-Y.;Su, P.-L.;Huang, W.-L.;Chang, Chang C.-C.;Yen, Yen Y.-T.;Lin, C.-C.;Tseng, Y.-L. |
| 臺大學術典藏 |
2021-08-12T04:01:31Z |
A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor
|
YANG SHIH-HUNG; Lin C.-C.; Lin Z.-Z.; Tseng Y.-L.; Hong R.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:48Z |
A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor
|
Yang S.-H.; Lin C.-C.; ZHONG-ZHE LIN; Tseng Y.-L.; Hong R.-L. |
| 臺大學術典藏 |
2021-08-10T03:53:07Z |
A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor
|
SHIH-HUNG YANG; Lin C.-C.; Lin Z.-Z.; Tseng Y.-L.; Hong R.-L. |
| 臺大學術典藏 |
2021-07-06T07:01:15Z |
Discovery of novel agents on spindle assembly checkpoint to sensitize vinorelbine-induced mitotic cell death against human non-small cell lung cancers
|
Chang Y.-C.; Tseng Y.-L.; Leu W.-J.; Du C.-M.; Jiang Y.-H.; LIH-CHING HSU; Hsu J.-L.; Hou D.-R.; Guh J.-H. |
| 臺大學術典藏 |
2021-06-02T05:43:20Z |
Discovery of novel agents on spindle assembly checkpoint to sensitize vinorelbine-induced mitotic cell death against human non-small cell lung cancers
|
Chang Y.-C.;Tseng Y.-L.;Leu W.-J.;Du C.-M.;Jiang Y.-H.;Hsu L.-C.;Hsu J.-L.;Hou D.-R.;Jih-Hwa Guh; Chang Y.-C.; Tseng Y.-L.; Leu W.-J.; Du C.-M.; Jiang Y.-H.; Hsu L.-C.; Hsu J.-L.; Hou D.-R.; JIH-HWA GUH |
| 臺大學術典藏 |
2021-05-31T07:03:26Z |
Inhibitory effects of human alpha2-macroglobulin and mouse serum on the PSGL-1 and glycoprotein Ib proteolysis by a snake venom metalloproteinase, triflamp
|
Tseng Y.-L.; Wu W.-B.; Hsu C.-C.; Peng H.-C.; TUR-FU HUANG |
| 臺大學術典藏 |
2021-05-31T07:03:26Z |
Effects of a snake venom metalloproteinase, triflamp, on platelet aggregation, platelet-neutrophil and neutrophil-neutrophil interactions: Involvement of platelet GPlbalpha and neutrophil PSGL-I
|
Tseng Y.-L.; Lee C.-J.; TUR-FU HUANG |
| 臺大學術典藏 |
2021-05-31T07:03:26Z |
Triflamp, a snake venom matalloproteinase, reduces neutrophil-platelet adhesion through proteolysis of PSGL-I but not glycoprotein lbalpha
|
Tseng Y.-L.; Lee C.-J.; Hsu C.-C.; TUR-FU HUANG |
| 臺大學術典藏 |
2021-05-31T07:03:25Z |
Rhodostomin, a disintegrin, inhibits adhesion of neutrophils to fibrinogen and attenuates superoxide production
|
Tseng Y.-L.; Peng H.-C.; TUR-FU HUANG |
| 臺大學術典藏 |
2021-05-31T07:03:19Z |
A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation
|
Tseng Y.-L.; Chiang M.-L.; TUR-FU HUANG; Su K.-P.; Lane H.-Y.; Lai Y.-C. |
| 臺大學術典藏 |
2021-05-31T07:03:18Z |
Improvements in endotoxemic syndromes using a disintegrin, rhodostomin, through integrin alphav beta 3-dependent pathway
|
Hsu C.-C.; Chuang W.-J.; Chang C.-H.; Tseng Y.-L.; Peng H.-C.; TUR-FU HUANG |
| 臺大學術典藏 |
2021-05-31T07:03:16Z |
Triflamp (Trimeresurus flavoviridis)
|
Tseng Y.-L.; TUR-FU HUANG |
| 臺大學術典藏 |
2021-03-09T06:46:17Z |
Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study
|
Ruey-Long Hong;Tseng Y.-L.;Chang F.-H.; RUEY-LONG HONG; Tseng Y.-L.; Chang F.-H. |
| 臺大學術典藏 |
2021-03-09T06:46:17Z |
Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficial?
|
Ruey-Long Hong;Huang C.-J.;Tseng Y.-L.;Pang V.F.;Chen S.-T.;Liu J.-J.;Chang F.-H.; RUEY-LONG HONG; Huang C.-J.; Tseng Y.-L.; Pang V.F.; Chen S.-T.; Liu J.-J.; Chang F.-H. |
| 臺大學術典藏 |
2021-03-09T06:46:17Z |
Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model
|
Tseng Y.-L.;Ruey-Long Hong;Tao M.-H.;Chang F.-H.; Tseng Y.-L.; RUEY-LONG HONG; Tao M.-H.; Chang F.-H. |
| 臺大學術典藏 |
2021-03-09T06:46:16Z |
Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: The relation between pharmacokinetic property and toxicity
|
Ruey-Long Hong;Tseng Y.-L.; RUEY-LONG HONG; Tseng Y.-L. |
| 臺大學術典藏 |
2021-03-09T06:46:14Z |
Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and Tat: A kinetic and efficacy study
|
Tseng Y.-L.;Liu J.-J.;Ruey-Long Hong; Tseng Y.-L.; Liu J.-J.; RUEY-LONG HONG |
| 臺大學術典藏 |
2021-03-09T06:46:14Z |
Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: Stability, pharmacokinetic and therapeutic evaluation
|
Liu J.-J.;Ruey-Long Hong;Cheng W.-F.;Hong K.;Chang F.-H.;Tseng Y.-L.; Liu J.-J.; RUEY-LONG HONG; Cheng W.-F.; Hong K.; Chang F.-H.; Tseng Y.-L. |
| 臺大學術典藏 |
2021-03-09T06:46:13Z |
A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma
|
Ruey-Long Hong;Tseng Y.-L.; RUEY-LONG HONG; Tseng Y.-L. |
| 臺大學術典藏 |
2021-03-09T06:46:07Z |
A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor
|
Yang S.-H.; Lin C.-C.; Lin Z.-Z.; Tseng Y.-L.; RUEY-LONG HONG |
| 臺大學術典藏 |
2021-01-06T08:23:24Z |
High concentration of C5a-induced mitochondria-dependent apoptosis in murine kidney endothelial cells
|
Tsai I.-J.;Lin W.-C.;Yao-Hsu Yang;Tseng Y.-L.;Lin Y.-H.;Chou C.-H.;Tsau Y.-K.; Tsai I.-J.; Lin W.-C.; YAO-HSU YANG; Tseng Y.-L.; Lin Y.-H.; Chou C.-H.; Tsau Y.-K. |
| 國立成功大學 |
2021 |
Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment
|
Su, P.-L.;Tsai, J.-S.;Yang, S.-C.;Wu, Y.-L.;Tseng, Y.-L.;Chang, Chang C.-C.;Yen, Yen Y.-T.;Lin, C.-Y.;Lin, C.-C.;Wang, C.-C.;Lin, M.-C.;Su, W.-C. |
